EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study) (EROS+CP (US) Trial)
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: N/A
Waitlist Available
Sponsor: AstraZeneca
No Placebo Group
Trial Summary
What is the purpose of this trial?A retrospective real-world data study, assessing the relationship between the timing of Budesonide/Glycopyrrolate/Formoterol initiation following an exacerbation and the occurrence of subsequent exacerbations, severe cardiopulmonary events and other real-world outcomes in the United States
Eligibility Criteria
Treatment Details
3Treatment groups
Experimental Treatment
Group I: VERY DELAYEDExperimental Treatment1 Intervention
PATIENTS INITIATING BGF WITHIN 181-365 DAYS OF EXACERBATION
Group II: PromptExperimental Treatment1 Intervention
PATIENTS INITIATING BGF WITHIN 30-DAYS OF EXACERBATION
Group III: DELAYEDExperimental Treatment1 Intervention
PATIENTS INITIATING BGF WITHIN 31-180 DAYS OF EXACERBATION
Find a clinic near you
Research locations nearbySelect from list below to view details:
AstraZenecaWilmington, DE
Loading ...
Who is running the clinical trial?
AstraZenecaLead Sponsor